Skip to main content

Journal of Cancer Research and Clinical Oncology

Ausgabe 1/2021

Inhalt (29 Artikel)

Editorial

A note from the editors

Klaus Hoeffken, Laura Walsh

Review – Cancer Research

MAPK signaling pathway-targeted marine compounds in cancer therapy

Jiaen Wei, Ruining Liu, Xiyun Hu, Tingen Liang, Zhiran Zhou, Zunnan Huang

Open Access Original Article – Cancer Research

Response rate and safety in patients with hepatocellular carcinoma treated with transarterial chemoembolization using 40-µm doxorubicin-eluting microspheres

Katharina Carolin Albrecht, René Aschenbach, Ioannis Diamantis, Niklas Eckardt, Ulf Teichgräber

Original Article – Cancer Research

High Wilms’ tumor 1 associating protein expression predicts poor prognosis in acute myeloid leukemia and regulates m6A methylation of MYC mRNA

Duolan Naren, Tianyou Yan, Yuping Gong, Jingcao Huang, Dan Zhang, Lina Sang, Xue Zheng, Yarong Li

Original Article – Cancer Research

Panel of potential lncRNA biomarkers can distinguish various types of liver malignant and benign tumors

Olga Y. Burenina, Natalia L. Lazarevich, Inna F. Kustova, Daria A. Shavochkina, Ekaterina A. Moroz, Nikolay E. Kudashkin, Yuriy I. Patyutko, Alexey V. Metelin, Eduard F. Kim, Dmitry A. Skvortsov, Timofei S. Zatsepin, Maria P. Rubtsova, Olga A. Dontsova

Open Access Original Article – Cancer Research

Stratification of Stage III colon cancer may identify a patient group not requiring adjuvant chemotherapy

Yasir G. Malik, Lars Gustav Lyckander, Jonas C. Lindstrøm, Olof Vinge-Holmquist, Ariba E. Sheikh, Johannes K. Schultz, Dejan Ignjatovic

Open Access Original Article – Cancer Research

Antineoplastic effects of targeting CCR5 and its therapeutic potential for colorectal cancer liver metastasis

Asim Pervaiz, Michael Zepp, Rania Georges, Frank Bergmann, Saqib Mahmood, Syeda Faiza, Martin R. Berger, Hassan Adwan

Original Article – Cancer Research

Gemcitabine potentiates anti-tumor effect of resveratrol on pancreatic cancer via down-regulation of VEGF-B

Yinan Yang, Wencong Tian, Lei Yang, Qiong Zhang, Mengmeng Zhu, Yuansheng Liu, Jing Li, Liang Yang, Jie Liu, Yanna Shen, Zhi Qi

Original Article – Cancer Research

Elevated ZBTB7A expression in the tumor invasive front correlates with more tumor budding formation in gastric adenocarcinoma

Yujing Sun, Junyi He, Duan-Bo Shi, Hui Zhang, Xu Chen, Ai-Yan Xing, Peng Gao

Original Article – Cancer Research

Analysis of genomic pathogenesis according to the revised Bethesda guidelines and additional criteria

Jin Cheon Kim, Jong Hwan Kim, Ye Jin Ha, Chan Wook Kim, Ka Hee Tak, Yong Sik Yoon, Yi Hong Kwon, Seon Ae Roh, Dong-Hyung Cho, Seon-Kyu Kim, Seon-Young Kim, Yong Sung Kim

Original Article – Cancer Research

B-MYB—p53-related relevant regulator for the progression of clear cell renal cell carcinoma

M. Nientiedt, K. Müller, K. Nitschke, P. Erben, A. Steidler, S. Porubsky, Z. V. Popovic, F. Waldbillig, J. Mühlbauer, M. C. Kriegmair

Original Article – Cancer Research

Association between the use of aspirin and risk of lung cancer: results from pooled cohorts and Mendelian randomization analyses

Yu Jiang, Zixuan Su, Caichen Li, Runchen Wang, Yaokai Wen, Hengrui Liang, Jianxing He, Wenhua Liang

Original Article – Cancer Research

An immune-related gene signature for determining Ewing sarcoma prognosis based on machine learning

En-hui Ren, Ya-jun Deng, Wen-hua Yuan, Zuo-long Wu, Guang-zhi Zhang, Qi-qi Xie

Original Article – Cancer Research

MET canonical transcript expression is a predictive biomarker for chemo-sensitivity to MET-inhibitors in hepatocellular carcinoma cell lines

Wafaa M. Rashed, Mohamed A. Kandeil, Mohamed O. Mahmoud, Doha Maher, Sameera Ezzat, Mohamed H. Abdel-Rahman

Original Article – Cancer Research

Mendelian randomization study indicates lack of causal relationship between physical activity and lung cancer

Wei Xian, Jiayi Shen, Huaqiang Zhou, Jiaqing Liu, Yaxiong Zhang, Zhonghan Zhang, Ting Zhou, Shaodong Hong, Yunpeng Yang, Wenfeng Fang, Hongyun Zhao, Yan Huang, Li Zhang

Original Article – Cancer Research

BRAFV600E, hypothyroidism, and human relaxin in thyroid carcinogenesis

Brenda Y. Hernandez, Mobeen Rahman, Lenora W. M. Loo, Owen T. M. Chan, David Horio, Shane Morita, Gillian Bryant-Greenwood

Open Access Review – Clinical Oncology

Risk of lung cancer and renin–angiotensin blockade: a concise review

Tobias Rachow, Helmut Schiffl, Susanne M. Lang

Open Access Original Article – Clinical Oncology

Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers

Dorothea Hose, Martin Schreder, Jochen Hefner, Max Bittrich, Sophia Danhof, Susanne Strifler, Maria-Theresa Krauth, Renate Schoder, Bettina Gisslinger, Hermann Einsele, Heinz Gisslinger, Stefan Knop

Original Article – Clinical Oncology

A nanowire-based liquid biopsy method using cerebrospinal fluid cell-free DNA for targeted management of leptomeningeal carcinomatosis

Wonyoung Choi, Youngnam Cho, Seog-Yun Park, Kum Hui Hwang, Ji-Youn Han, Youngjoo Lee

Original Article – Clinical Oncology

Stem signatures associated antibodies yield early diagnosis and precise prognosis predication of patients with non-small cell lung cancer

Si-Si Chen, Kai Li, Jie Wu, Zi-Yang Peng, Zhi-Dong Wang, Ji-Chang Wang, Chong-Wen Xu, Cai-lin Zhu, Bao-Cheng Li, Hong Ren, Shou-Ching Tang, Xin Sun

Open Access Original Article – Clinical Oncology

Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial)

Thomas Wiegel, Peter Albers, Detlef Bartkowiak, Roswitha Bussar-Maatz, Martin Härter, Glen Kristiansen, Peter Martus, Stefan Wellek, Heinz Schmidberger, Klaus Grozinger, Peter Renner, Fried Schneider, Martin Burmester, Michael Stöckle

Correction

Correction to: Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial)

Thomas Wiegel, Peter Albers, Detlef Bartkowiak, Roswitha Bussar-Maatz, Martin Härter, Glen Kristiansen, Peter Martus, Stefan Wellek, Heinz Schmidberger, Klaus Grozinger, Peter Renner, Fried Schneider, Martin Burmester, Michael Stöckle

Open Access Original Article – Clinical Oncology

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression

Ken Masuda, Hidehito Horinouchi, Midori Tanaka, Ryoko Higashiyama, Yuki Shinno, Jun Sato, Yuji Matsumoto, Yusuke Okuma, Tatsuya Yoshida, Yasushi Goto, Noboru Yamamoto, Yuichiro Ohe

Open Access Original Article – Clinical Oncology

Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide

Kerstin Berger, Bernd Turowski, Jörg Felsberg, Bastian Malzkorn, Guido Reifenberger, Hans-Jakob Steiger, Wilfried Budach, Jan Haussmann, Johannes Knipps, Marion Rapp, Daniel Hänggi, Michael Sabel, Hendrik-Jan Mijderwijk, Marcel A. Kamp

Open Access Original Article – Clinical Oncology

Clinical responses to PD-1 inhibition and their molecular characterization in six patients with mismatch repair-deficient metastatic cancer of the digestive system

Daniela Hirsch, Timo Gaiser, Kirsten Merx, Simone Weingaertner, Michael Forster, Alexander Hendricks, Matthias Woenckhaus, Thomas Schubert, Ralf-Dieter Hofheinz, Deniz Gencer

Original Article – Clinical Oncology

A prediction model to evaluate the pretest risk of malignancy in solitary pulmonary nodules: evidence from a large Chinese southwestern population

Zuohong Wu, Tingting Huang, Shiqi Zhang, Deyun Cheng, Weimin Li, Bojiang Chen

Letter to the Editor

Peripheral blood T lymphocytosis in thymoma: an insight into immunobiology

Shruti Mishra, Somanath Padhi, Amit Kumar Adhya, Saroj Kumar DasMajumdar, Ashutosh Pattnaik, Gaurav Chhabra

ACKNOWLEDGEMENT TO REVIEWERS

Reviewer Acknowledgements 2020

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.